Verdera Energy Corp. has initiated a new normal course issuer bid (NCIB) to repurchase up to 6.39 million common shares, reflecting its increased share capital following a recent distribution to enCore Energy shareholders. This new buyback replaces the previous NCIB, which ended early after purchasing 380,500 shares. The program aims to buy back about 9.44% of the adjusted public float and will run until November 5, 2027, or until the maximum shares are bought. The move signals Verdera's strategy to use available capital effectively amid its uranium development projects in New Mexico.
Verdera Energy Corp.'s new normal course issuer bid is the subject here, with Pluang providing energy sector market data for context. Of 79 priced US energy stocks on Pluang, 19 rose and 55 fell today. Notable movers include NXE at USD 8.47 (+2.29%), NXT at USD 81.16 (+2.29%), and PBF at USD 76.40 (-2.05%), as of Nov 02, 2026 19:11 WIB.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
